Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Droplet digital PCR (ddPCR)-based blood detection of EGFR mutations plays significant roles in the individualized therapy of non-small-cell lung cancer (NSCLC) patients. However, a standard assay that is approved by health authorities is still lacking. Additionally, the proper application of this method in clinical settings also needs further investigation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The performance of a newly established ddPCR assay was first evaluated using reference samples and then validated by comparing this method with the amplification refractory mutation system (ARMS) using cell-free DNA (cfDNA) in patients' peripheral blood. Further, the correlation between dynamic quantification of EGFR mutation in the patients and their clinical outcome of tyrosine kinase inhibitors (TKIs) therapy was investigated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>A total of 77 patients were included, with 50 in the test group and 27 in the validation group. According to the results of the reference samples and the blood samples in the test group, the cut-off value for patient detection was proposed as mutation rate ≥ 0.1% (total copy number of cfDNA ≥1,000) or at least one copy of mutation DNA was detected (total copy number of cfDNA <1,000). With this criterion, superior sensitivity of our assay to that of ARMS was observed (<em>P</em>=0.002 for Ex19Del & L858R and <em>P</em><0.001 for T790M). The dynamic quantification of EGFR mutations during TKI therapy indicated that an increase in mutation abundance was correlated with resistance, while a decline was associated with response. Notably, a rebound in mutation abundance during chemotherapy may indicate a desirable chance for TKI re-treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>The novel ddPCR assay showed superior sensitivity in the detection of EGFR mutation in blood. The dynamic quantification of EGFR mutations by this assay would greatly facilitate the administration of TKI therapy, including the monitoring of resistance and response, as well as cohort screening for retreatment.</p>

Construction of the method for quantitative detection of epidermal growth factor receptor variant Ⅲ by real-time polymerase chain reaction with Taq Man probe and its application

Quantitative analysis of epidermal growth factor receptor mRNA in laryngeal carcinoma by reverse transcription-real time polymerase chain reaction with TagMan probe]

Quantitative detection of AMACR mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction (FQ-RT-PCR) and the clinical significance

Expression of Epidermal Growth Factor Receptor Variant Iii in Laryngeal Carcinoma Tissues

Measurement of the Mrna Level of Polo-like Kinase 1 in Bronchoscopic Bioptic Specimens by Real-Time Quantitative PCR

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Quantification of Epidermal Growth Factor Receptor T790M Mutant Transcripts in Lung Cancer Cells by Real-Time Reverse Transcriptase–quantitative Polymerase Chain Reaction

Simultaneous amplification of exons 18 to 21 of the EGFR gene using 5' tailed primers and a two-stage protocol

Establishment of multiplex allele-specific blocker PCR for enrichment and detection of 4 common EGFR mutations in non-small cell lung cancer

A Simple and Rapid Method for Detecting Major Mutations of Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

Establishment of a Digital PCR Platform for Detection of EGFR T790M Mutation in Plasma Circulating DNA from NSCLC Patients

Peptide–Au Cluster Probe: Precisely Detecting Epidermal Growth Factor Receptor of Three Tumor Cell Lines at a Single-Cell Level

Highly-selective detection of EGFR mutation gene in lung cancer based on surface enhanced Raman spectroscopy and asymmetric PCR

Detection of TERC Amplification in Cervical Epithelial Cells for the Diagnosis of High-Grade Cervical Lesions and Invasive Cancer: A Multicenter Study in China

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients

Comparison of EGFR mutations in blood and tumor tissue samples by allele-specific PCR

TtAgo-coupled-multiplex-digtal-RPA-CRISPR/Cas12a (TCMDC) for EGFR mutations detection

[High-Resolution Melting Analysis for the Detection of EGFR Mutations in Circulating DNA of Lung Cancer Patients].

A high-sensitivity detection method for plasma EGFR exon 19 deletion

Ultrasensitive and Quantitative Detection of EGFR Mutations in Plasma Samples from Patients with Non-Small-cell Lung Cancer Using a Dual PNA Clamping-Mediated LNA-PNA PCR Clamp

Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients